Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy

References

• Komers R, Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R877–R884. doi: 10.1152/ajpregu.00425.2015
   PubMed Web of Science ®Google Scholar
• Zhong J, Yang HC, Fogo AB. A perspective on chronic kidney disease progression. Am J Physiol Renal Physiol. 2017;312(3):F375–F384. PMID: 27974318. doi: 10.1152/ajprenal.00266.2016
   PubMed Web of Science ®Google Scholar
• Vanhove T, Goldschmeding R, Kuypers D. Kidney fibrosis: origins and interventions. Transplantation. 2017;101(4):713–726. PMID: 27941433. doi: 10.1097/TP.0000000000001608
   PubMed Web of Science ®Google Scholar
• Cantero-Navarro E, Fernández-Fernández B, Ramos AM, et al. Renin-angiotensin system and inflammation update. Mol Cell Endocrinol. 2021;529:111254. PMID: 33798633 Review. doi: 10.1016/j.mce.2021.111254
   PubMed Web of Science ®Google Scholar
• Xu Z, Li W, Han J, et al. Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2). Sci Rep. 2017;7(1):44911. PMID: 28322341. doi: 10.1038/srep44911
   PubMedGoogle Scholar
• Aki K, Shimizu A, Masuda Y, et al. ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol. 2010;298(4):F870–F882. PMID: 20071465. doi: 10.1152/ajprenal.00374.2009
   PubMed Web of Science ®Google Scholar
• Chan CT, Sobey CG, Lieu M, et al. Obligatory role for B cells in the development of angiotensin II-Dependent hypertension. Hypertension. 2015 Nov;66(5):1023–1033. PMID: 26351030. doi: 10.1161/HYPERTENSIONAHA.115.05779
   PubMed Web of Science ®Google Scholar
• Wade B, Petrova G, Mattson DL. Role of immune factors in angiotensin II-induced hypertension and renal damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol. 2018;314(3):R323–R333. PMID: 29118017. doi: 10.1152/ajpregu.00044.2017
   PubMed Web of Science ®Google Scholar
• Saleh MA, Boesen EI, Pollock JS, et al. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension. 2010;56(5):942–949. PMID: 20823379. doi: 10.1161/HYPERTENSIONAHA.110.156570
   PubMed Web of Science ®Google Scholar
• Boesen EI. ETA receptor activation contributes to T cell accumulation in the kidney following ischemia-reperfusion injury. Physiol Rep. 2018;6(17):e13865. PMID: 30198212. doi: 10.14814/phy2.13865
   PubMedGoogle Scholar
• Cosgrove D, Gratton MA, Madison J, et al. Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice. J Pathol. 2023 Jul;260(3):353–364. PMID: 37256677. doi: 10.1002/path.6087
   PubMed Web of Science ®Google Scholar
• Gyarmati G, Deepak S, Shroff U, et al. Sparsentan improves glomerular endothelial and podocyte functions and augments protective tissue repair in a mouse model of focal segmental glomerulosclerosis (FSGS). Orlando (FL): ASN; 2022 Nov 3-6.
   Google Scholar
• Nagasawa H, Suzuki H, Jenkinson C, et al. The Dual Endothelin Type a Receptor (ETAR) and angiotensin II Type 1 Receptor (AT1R) antagonist, sparsentan, protects against the development of Albuminuria and glomerulosclerosis in the gddY mouse model of IgA nephropathy. USA: ASN. Kidney Week. PO1808; 2020.
   Google Scholar
• Reily C, Moldoveanu Z, Pramparo T, et al. The dual endothelin angiotensin receptor antagonist (Deara) sparsentan protects from glomerular hypercellularity and associated Immune/Inflammatory gene-network-activity in a Model of iga nephropathy (igan). USA.: ASN. Kidney Week. PO1454; 2021.
   Google Scholar
• Boesen EI, Krishnan KR, Pollock JS, et al. ETA activation mediates angiotensin II-induced infiltration of renal cortical T cells. J Am Soc Nephrol. 2011;22(12):2187–2192. PMID: 22021713. doi: 10.1681/ASN.2010020193
   PubMed Web of Science ®Google Scholar
• Tycová I, Hrubá P, Maixnerová D, et al. Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis. Physiol Res. 2018;67(1):93–105. PMID: 29137483. doi: 10.33549/physiolres.933670
   PubMed Web of Science ®Google Scholar
• Li L, Tang W, Zhang Y, et al. Targeting tissue-resident memory CD8+ T cells in the kidney is a potential therapeutic strategy to ameliorate podocyte injury and glomerulosclerosis. Mol Ther. 2022;30(8):2746–2759. doi: 10.1016/j.ymthe.2022.04.024
   PubMed Web of Science ®Google Scholar
• van de Lest NA, Bakker AE, Dijkstra KL, et al. Endothelial endothelin receptor a expression is associated with podocyte injury and oxidative stress in patients with focal segmental glomerulosclerosis. Kidney Int Rep. 2021;6(7):1939–1948. doi: 10.1016/j.ekir.2021.04.013
   PubMed Web of Science ®Google Scholar
• Lassén E, Daehn IS. Clues to Glomerular Cell Chatter in Focal Segmental Glomerulosclerosis: Via Endothelin-1/ET A R. Kidney Int Rep. 2021;6(7):1758–1760. doi: 10.1016/j.ekir.2021.05.013
   PubMed Web of Science ®Google Scholar
• Lehrke I, Waldherr R, Ritz E, et al. Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol. 2001;12(11):2321–2329. doi: 10.1681/ASN.V12112321
   PubMed Web of Science ®Google Scholar
• Gesualdo L, Di Leo V, Coppo R. Coppo R the mucosal immune system and IgA nephropathy. Semin Immunopathol. 2021;43(5):657–668. PMID: 34642783. doi: 10.1007/s00281-021-00871-y
   PubMed Web of Science ®Google Scholar
• Liu L, Khan A, Sanchez-Rodriguez E, et al. Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits. Nat Commun. 2022;13(1):6859. PMID: 36369178. doi: 10.1038/s41467-022-34456-6
   PubMed Web of Science ®Google Scholar
• Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187–1196. PMID: 25305756. doi: 10.1038/ng.3118
   PubMed Web of Science ®Google Scholar
• Placzek WJ, Yanagawa H, Makita Y, et al. Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. PloS One. 2018;13(1):e0190967. PMID: 29324897. doi: 10.1371/journal.pone.0190967
   PubMed Web of Science ®Google Scholar
• Makita Y, Suzuki H, Kano T, et al. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 2020;97(2):340–349. PMID: 31748116. doi: 10.1016/j.kint.2019.08.022
   PubMed Web of Science ®Google Scholar
• Qing J, Li C, Hu X, et al. Differentiation of T helper 17 cells may mediate the abnormal humoral immunity in IgA nephropathy and inflammatory bowel disease based on shared genetic effects. Front Immunol. 2022;13:916934. PMID: 35769467. doi: 10.3389/fimmu.2022.916934
   PubMed Web of Science ®Google Scholar
• Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. IgAN classification working group of the International IgA nephropathy network and the renal pathology society; conference participants. Kidney Int. 2017;91(5):1014–1021. PMID: 28341274. doi: 10.1016/j.kint.2017.02.003
   PubMed Web of Science ®Google Scholar
• Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38(5):435–442. PMID: 30177015. doi: 10.1016/j.semnephrol.2018.05.013
   PubMed Web of Science ®Google Scholar
• Kiryluk K, Sanchez-Rodriguez E, Zhou XJ, et al. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet. 2023;55(7):1091–1105. PMID: 37337107. doi: 10.1038/s41588-023-01422-x
   PubMed Web of Science ®Google Scholar
• Hastings MC, Rizk DV, Kiryluk K, et al. IgA vasculitis with nephritis: update of pathogenesis with clinical implications. Pediatr Nephrol. 2022;37(4):719–733. PMID: 33818625. doi: 10.1007/s00467-021-04950-y
   PubMed Web of Science ®Google Scholar
• Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727–738. PMID: 37055195. doi: 10.2215/CJN.0000000000000135
   PubMed Web of Science ®Google Scholar
• Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12(3):502–517. PMID: 28242845. doi: 10.2215/CJN.05960616
   PubMed Web of Science ®Google Scholar
• Barratt J, Rovin B, Wong MG, et al. PROTECT investigators. IgA nephropathy patient baseline characteristics in the sparsentan PROTECT study. Kidney Int Rep. 2023;8(5):1043–1056. PMID: 37180506. doi: 10.1016/j.ekir.2023.02.1086
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Radhakrishnan J, Alpers CE, et al. PROTECT investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. J Obstet Gynaecol. 2023;401(10388):1584–1594. doi: 10.1016/S0140-6736(23)00569-X
   Google Scholar
• Sparsentan Versus Irbesartan in Focal Segmental Glomerulosclerosis, Rheault MN, Alpers CE, Barratt J, et al. DUPRO steering committee and DUPLEX investigators. N Engl J Med. 2023;389(26):2436–2445. PMID: 37921461. doi: 10.1056/NEJMoa2308550
   PubMedGoogle Scholar
• Rovin BH, Barratt J, Heerspink HJL, et al. DUPRO steering committee and PROTECT investigators. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077–2090. Online ahead of print. PMID: 37931634. doi: 10.1016/S0140-6736(23)02302-4
   PubMed Web of Science ®Google Scholar
• Fornoni A, Rodriguez J, Drexler Y. Novel Therapies for Alport Syndrome. Front Med. 2022;9:848389. doi: 10.3389/fmed.2022.848389
   Web of Science ®Google Scholar
• Tuttle KR, Levin A, Nangaku M, et al. Safety of Empagliflozin in patients with type 2 diabetes and chronic kidney disease: pooled analysis of placebo-controlled clinical trials. Diabetes Care. 2022;45(6):1445–1452. PMID: 35472672. doi: 10.2337/dc21-2034
   PubMed Web of Science ®Google Scholar
• Thompson A, Carroll K, AInker L, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469–481. doi: 10.2215/CJN.08600718
   PubMed Web of Science ®Google Scholar
• Troost JP, Trachtman H, Nachman PH, et al. An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2018;13(3):414–421. doi: 10.2215/CJN.04780517
   PubMed Web of Science ®Google Scholar
• Trachtman H, Coppo R, Saleem M, et al. Maximizing the value of the open label extension phase of randomized clinical trials. J Nephrol. 2023 Jan;6(6):1–3. doi: 10.1007/s40620-022-01542-3
   Google Scholar
• Trachtman H, Desmond H, Williams AL, et al. NEPTUNE investigators. Rationale and design of the nephrotic syndrome study network (NEPTUNE) match in glomerular diseases: designing the right trial for the right patient, today. Kidney Intern. 2024;105(2):218–230. PMID: 38245210. doi: 10.1016/j.kint.2023.11.018
   PubMed Web of Science ®Google Scholar
• Lafayette R, Kristensen J, Stone A, et al. NefIgArd trial investigators. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgard): 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859–870. doi: 10.1016/S0140-6736(23)01554-4
   PubMed Web of Science ®Google Scholar
• Mathur M, Barratt J, Chacko B, et al. ENVISION trial investigators group. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2023 Nov 2;390(1):20–31. Online ahead of print. PMID: 37916620. doi: 10.1056/NEJMoa2305635
   PubMedGoogle Scholar
• Lafayette RA, Rovin BH, Reich HN, et al. Tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy. Kidney Int Rep. 2020;5(11):2032–2041. doi: 10.1016/j.ekir.2020.08.003
   PubMed Web of Science ®Google Scholar
• El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA nephropathy: a rapidly evolving field. J Am Soc Nephrol. 2024;35(1):103–116. PMID: 37772889. doi: 10.1681/ASN.0000000000000242
   PubMed Web of Science ®Google Scholar